Latest Content

Riozzi Bodine shares how her daughter’s diagnosis inspired the launch of a foundation offering cold caps, wigs and caregiver support.

A nurse practitioner explains how FDA approval of subcutaneous Rybrevant may reduce treatment burden and improve care for patients with EGFR-mutated lung cancer.

New research shows specific chemotherapies and radiation increase the risk of subsequent brain tumors in long-term childhood cancer survivors.

Showing up taking notes and learning the disease can help families feel empowered as new treatments expand hope and quality of life.

Laura Yeager reflects on losses from theft and cancer, showing how resilience grows and gratitude emerges even after life's hardest setbacks.

CURE spoke with a provider and a survivor about the potential power of minimal residual disease testing.

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda.

The FDA approved protocol updates to a tasquinimod trial in myelofibrosis, allowing broader enrollment and combination use with JAK inhibitors.

In an interview, liver cancer survivor Charles Walker shared how family support and a living donor transplant changed his treatment journey and outlook.

FDA OKs Keytruda with paclitaxel for PD-L1 positive, platinum-resistant ovarian, fallopian tube or peritoneal cancers, improving survival and delaying growth.

Charles Walker joins CURE’s Gina Mauro to share his long and road to a liver cancer diagnosis and the importance of being your own medical advocate.

Former NFL player and advocate Chris Draft urges patients with cancer to recognize small actions, learn terms and stay engaged to rebuild confidence after diagnosis.

Amid the grief that I have and continue to deal with due to my sister’s death from cancer, I have been blessed with phenomenal support.